SB 239063
Chemical Name: trans-4-[4-(4-Fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol
Purity: ≥98%
Biological Activity
SB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38α). Displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580 (Cat. Nos. 1202 and 1402). Reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Additional Information
Background References
-
Sirt1, p53, and p38(MAPK) Are Crucial Regulators of Detrimental Phenotypes of Embryonic Stem Cells with Max Expression Ablation.
Hishida T, Nozaki Y, Nakachi Y, Mizuno Y, Iseki H, Katano M, Kamon M, Hirasaki M, Nishimoto M, Okazaki Y, Okuda A
Stem Cells, 2012;30(8):1634-44. -
Regulation of the CCL2 Gene in Pancreatic beta-Cells by IL-1beta and Glucocorticoids: Role of MKP-1.
Burke S, Goff M, Updegraff B, Lu D, Brown P, Minkin S, Biggerstaff J, Zhao L, Karlstad M, Collier J
PLoS ONE, 2012;7(10):e46986. -
Alamandine reduces leptin expression through the c-Src/p38 MAP kinase pathway in adipose tissue
T Uchiyama, F Okajima, C Mogi, A Tobo, S Tomono, K Sato
PLoS ONE, 2017;12(6):e0178769. -
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.
Barone et al.
J.Pharmacol.Exp.Ther., 2001;296:312 -
The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury.
Legos et al.
Eur.J.Pharmacol., 2002;447:37 -
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood et al.
J.Pharmacol.Exp.Ther., 2000;293:281
Product Datasheets
Citations for SB 239063
The citations listed below are publications that use Tocris products. Selected citations for SB 239063 include:
8 Citations: Showing 1 - 8
-
Hyperammonemia alters membrane expression of GluA1 and GluA2 subunits of AMPA receptors in hippocampus by enhancing activation of the IL-1 receptor: underlying mechanisms.
Authors: Taoro-Gonzalez Et al.
J Neuroinflammation 2018;15:36
-
Delayed activation of spinal microglia contributes to the maintenance of bone cancer pain in female Wistar rats via P2X7 receptor and IL-18.
Authors: Yang Et al.
J Neurosci 2015;35:7950
-
Rats with minimal hepatic encephalopathy due to portacaval shunt show differential increase of translocator protein (18 kDa) binding in different brain areas, which is not affected by chronic MAP-kinase p38 inhibition.
Authors: Agusti Et al.
J Mol Neurosci 2014;29:955
-
Separate cyclic AMP sensors for neuritogenesis, growth arrest, and survival of neuroendocrine cells.
Authors: Emery Et al.
J Biol Chem 2014;289:10126
-
Caspases and p38 MAPK regulate endothelial cell adhesiveness for mesenchymal stem cells.
Authors: Potapova Et al.
Metab Brain Dis 2013;8:e73929
-
Neuropeptide Y inhibits interleukin-1β-induced phagocytosis by microglial cells.
Authors: Ferreira Et al.
PLoS One 2011;8:169
-
ERK signaling leads to mitochondrial dysfunction in extracellular zinc-induced neurotoxicity.
Authors: He and Aizenman
J Neurochem 2010;114:452
-
Interleukin-8 secretion by fibroblasts induced by low density lipoproteins is p38 MAPK-dependent and leads to cell spreading and wound closure.
Authors: Dobreva Et al.
J Biol Chem 2006;281:199
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for SB 239063
There are currently no reviews for this product. Be the first to review SB 239063 and earn rewards!
Have you used SB 239063?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
